Manuel Penedo Pita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manuel Penedo Pita has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ana Dorado Díaz
Department of Statistical Health Counselling, Junta de Castilla y León, 47001 Valladolid, Spain
1 shared publication - Carmen García-Plata González
Pediatric Gastrohepathology Unit of Hospital Universitario Lucus Augusti, 27003 Lugo, Spain
1 shared publication - José Paz Carreira
Department of Hematology, Oncology Center of Galicia, 15009 A Coruña, Spain
1 shared publication - Julia María Cabo del Riego
Clinical Analysis Laboratory, Department of Immunology, Lucus Augusti University Hospital, 27003 Lugo, Spain
1 shared publication - Lola Máiz Suárez
Clinical Analysis Laboratory, Department of Inmunology, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain
1 shared publication - Manuel Freire-Garabal
Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
1 shared publication
Latest Publications
- Open Access
- 20 April 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (9) , 5020
Evaluation of Celiac Disease by Minimally Invasive Biomarkers in a Spanish Pediatric Population
Background: The diagnosis of celiac disease (CD) has been substantially improved with the availability of highly sensitive CD-specific IgA-TG2, Ig-GDP, and IgA-EMA. The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) published (2012) and updated (2020) diagnostic criteria for CD in order to simplify CD diagnosis and to avoid biopsies in selected patients. Methods: A prospective study including 5641 pediatric patients (0–16 years old) from January 2012 to January 2019 was performed. CD diagnosis was made according to the ESPGHAN algorithm. The objective of this study was to evaluate the utility of biomarkers and the relationship between TGA-IgA and EMA titers. Results: CD diagnoses were confirmed in 113 patients, 110 were IgA-TG2-positive and 3 (2.7%) had IgA deficiency. The diagnosis was made by serologic tests in 95 (84.1%) patients. Only 18 (15.9%) patients underwent intestinal biopsy. We obtained 100% concordance between IgA-EMA and positive results for IgA-TG2 ≥ 10 ULN with IgA-EMA antibody titer ≥ 1:80. Conclusions: This study provides evidence of a positive correlation between IgA-TG2 antibody serum levels and IgA-EMA. The diagnosis could be guaranteed with strict application of IgA-TG2 values ≥ 10 ULN (confirmed by subsequent testing) plus the serological response to the gluten-free diet (GFD).
- 20 April 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (9) , 5020
Open AccessEvaluation of Celiac Disease by Minimally Invasive Biomarkers in a Spanish Pediatric Population
Background: The diagnosis of celiac disease (CD) has been substantially improved with the availability of highly sensitive CD-specific IgA-TG2, Ig-GDP, and IgA-EMA. The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) published (2012) and updated (2020) diagnostic criteria for CD in order to simplify CD diagnosis and to avoid biopsies in selected patients. Methods: A prospective study including 5641 pediatric patients (0–16 years old) from January 2012 to January 2019 was performed. CD diagnosis was made according to the ESPGHAN algorithm. The objective of this study was to evaluate the utility of biomarkers and the relationship between TGA-IgA and EMA titers. Results: CD diagnoses were confirmed in 113 patients, 110 were IgA-TG2-positive and 3 (2.7%) had IgA deficiency. The diagnosis was made by serologic tests in 95 (84.1%) patients. Only 18 (15.9%) patients underwent intestinal biopsy. We obtained 100% concordance between IgA-EMA and positive results for IgA-TG2 ≥ 10 ULN with IgA-EMA antibody titer ≥ 1:80. Conclusions: This study provides evidence of a positive correlation between IgA-TG2 antibody serum levels and IgA-EMA. The diagnosis could be guaranteed with strict application of IgA-TG2 values ≥ 10 ULN (confirmed by subsequent testing) plus the serological response to the gluten-free diet (GFD).